Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 2/20 | 0.62 |
| ▸ | PNP | P00491 | 10/20 | 0.60 |
| ▸ | BLM | P54132 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | EDNRA | P25101 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | HBB | P68871 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | VCP | P55072 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | HPRT1 | P00492 | 8/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8781788 | 0.93 | PNP (0.64) | TK1PNPBLMUSP2TSHR | |
| SCHEMBL9684292 | 0.85 | HPRT1 (0.69) | PNPHPRT1 | |
| SCHEMBL28297087 | 0.85 | PNP (0.51) | TK1PNPBLMUSP2TSHR | |
| SCHEMBL9683440 | 0.84 | PNP (0.70) | PNPHPRT1 | |
| SCHEMBL9183369 | 0.84 | PNP (0.49) | TK1PNPBLMUSP2TSHR | |
| SCHEMBL27503506 | 0.84 | PNP (0.53) | TK1PNPBLMUSP2TSHR | |
| SCHEMBL9184052 | 0.83 | BLM (0.54) | TK1PNPBLMUSP2TSHR | |
| SCHEMBL9857583 | 0.83 | HPRT1 (0.61) | PNPHPRT1 | |
| SCHEMBL27973331 | 0.82 | PNP (0.59) | TK1PNPBLMUSP2TSHR | |
| SCHEMBL15643286 | 0.81 | MEN1 (0.58) | TK1PNPBLMUSP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0242482-B1 | Antiviral purine derivatives and process for their preparation | BEECHAM GROUP PLC (GB) | 1995-09-06 | — | — | EP | claimed |
| US-4965270-A | Viricides | BEECHAM GROUP P.L.C. (GB) | 1990-10-23 | — | — | US | claimed |
| EP-0313289-A2 | Process for the preparation of purine compounds and intermediates therefor | BEECHAM GROUP PLC (GB) | 1989-04-26 | — | — | EP | claimed |
| EP-0242482-A2 | Antiviral purine derivatives and process for their preparation | BEECHAM GROUP PLC (GB) | 1987-10-28 | — | — | EP | claimed |
| US-7560587-B2 | Bis[urea-urethane] compounds | XEROX CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-7504502-B2 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080171877-A1 | GUANIDINOPYRIMIDINONE COMPOUNDS AND PHASE CHANGE INKS CONTAINING SAME | XEROX CORPORATION (US) | 2008-07-17 | — | — | US | disclosed |
| US-7371858-B2 | Guanidinopyrimidinone compounds and phase change inks containing same | XEROX CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| US-7317122-B2 | Curable trans-1,2-cyclohexane bis(urea-urethane) compounds | XEROX CORPORATION (US) | 2008-01-08 | — | — | US | disclosed |
| US-7314949-B2 | 1,2-bis(6-(ethylhexyloxycarbonylamino)hexylaminocarbonylamino)cyclohexane; gelling agents for hot melt and phase change inks | XEROX CORPORATION (US) | 2008-01-01 | — | — | US | disclosed |
| US-7220300-B2 | Phase change inks containing bis(urea-urethane) compounds | XEROX CORPORATION (US) | 2007-05-22 | — | — | US | disclosed |
| US-7157601-B2 | Alkylated urea and triaminotriazine compounds and phase change inks containing same | XEROX CORPORATION (US) | 2007-01-02 | — | — | US | disclosed |
| US-5252575-A | Herpes virus | BEECHAM GROUP P.L.C. (GB) | 1993-10-12 | — | — | US | disclosed |
| US-5159076-A | Purine intermediates | BEECHAM GROUP P.L.C. (GB) | 1992-10-27 | — | — | US | disclosed |
| EP-0413544-A2 | Purine derivatives, process for their preparation, pharmaceutical compositions and intermediates | Beecham Group p.l.c. (GB) | 1991-02-20 | — | — | EP | disclosed |
| EP-0413544-A2 | Purine derivatives, process for their preparation, pharmaceutical compositions and intermediates | Beecham Group p.l.c. (GB) | 1991-02-20 | — | — | EP | disclosed |
| US-4965270-A | Viricides | BEECHAM GROUP P.L.C. (GB) | 1990-10-23 | — | — | US | disclosed |
| US-4910307-A | Process for preparing purines | BEECHAM GROUP P.L.C. (GB) | 1990-03-20 | — | — | US | disclosed |
| EP-0313289-A2 | Process for the preparation of purine compounds and intermediates therefor | BEECHAM GROUP PLC (GB) | 1989-04-26 | — | — | EP | disclosed |
| EP-0242482-A2 | Antiviral purine derivatives and process for their preparation | BEECHAM GROUP PLC (GB) | 1987-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171877-A1 | GUANIDINOPYRIMIDINONE COMPOUNDS AND PHASE CHANGE INKS CONTAINING SAME | INO80, RPP30, RO60 | TK1 3607/4885PNP 2654/4885BLM 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.